Healthcare / BiotechnologySwiss
$23.20
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-433599.00 · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$134M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.5%
↓Gross Margin
3.4%
↓Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-35.5%
FCF CAGR
—
FCF margin
-463.2%
FCF / Net income
0.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $275313.0 · net income $-21.5M · FCF $-1.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $275313.00 | $275313.00 | $834877.00 | $988435.00 | $1.0M |
| Net Income | $-21.5M | $-21.5M | $34.3M | $14.9M | $14.3M |
| EBITDA | $-3.1M | $-3.1M | $40.5M | $20.9M | $20.7M |
| EPS | -3.76 | -3.76 | 4.69 | 2.08 | 2.00 |
| Gross Margin | 3.4% | 3.4% | 65.8% | 45.4% | 18.1% |
| Operating Margin | -11462.0% | -11462.0% | -2317.3% | -2054.6% | -2041.2% |
| Net Margin | -7826.5% | -7826.5% | 4105.6% | 1505.3% | 1392.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.19 | 0.21 | 0.26 |
| Current Ratio | 0.10 | 0.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.3M | $-1.3M | $-433599.00 | $130700.00 | $-4.7M |
| Returns | |||||
| ROE | -7.5% | -7.5% | 11.2% | 5.5% | 6.1% |
| Valuation | |||||
| P/E | — | — | 5.33 | 22.60 | 18.45 |
| EV/EBITDA | — | — | 5.99 | 18.94 | 15.80 |
| P/B | 0.59 | 0.59 | 0.60 | 1.27 | 1.14 |
| Growth & Yield | |||||
| Revenue Growth | -67.0% | -67.0% | -15.5% | -3.8% | — |
| EPS Growth | -180.2% | -180.2% | 125.5% | 4.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.3%
Start / end P/E
n/dx → n/dx
EPS bridge
4.69 → -3.76
Residual
+16.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.